Nitin Jain, MBBS
UT MD Anderson · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nitin Jain, MBBS as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07674810 · A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic LeukemiaM.D. Anderson Cancer Center · not yet recruiting · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT07674823 · Study Of KITE-753 in R/R B-Cell ALLM.D. Anderson Cancer Center · not yet recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT07508995 · A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)M.D. Anderson Cancer Center · recruiting · Chronic Lymphocytic Leukemia (CLL) · principal investigator
- Ph1NCT05961696 · A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · withdrawn · Refractory B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT02481297 · Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsM.D. Anderson Cancer Center · completed · Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia · principal investigator
- Ph2NCT02420938 · Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsM.D. Anderson Cancer Center · withdrawn · Leukemia · principal investigator
- Ph1/Ph2NCT02096042 · Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1/Ph2NCT01794702 · Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute LeukemiaM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.